the aid library

LIST OPTIONS

Filter

6813

Download (173)

View PDF (165)

Finding the Balance: Public health and social measures in Nigeria

Partnership for Evidence-Based Response to COVID-19 (PERC) (2021) CC

October 2021

Download (370)

View PDF (642)

Democratic Republic of Congo: PROFILE OF PRETERM AND LOW BIRTH WEIGHT PREVENTION AND CARE

Every Preemie—SCALE (2017) C2

The information provided here can be used to understand the current situation, increase attention to preterm births in Rwanda and to inform dialogue and action among stakeholders. Data can be used to identify the most important risk factors to target and gaps in care in order to identify and impleme... more

External Link

Social Mobilization and Community Engagement Central to the Ebola Response in West Africa: Lessons for Future Public Health Emergencies
recommended

Amaya M Gillespie, Rafael Obregon, Rania El Asawi, et al. (2016) CC

doi: 10.9745/GHSP-D-16-00226; Glob Health Sci Pract December 23, 2016 vol. 4 no. 4 p. 626-646

Download (346)

View PDF (456)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (189)

View PDF (232)

Prevention and control of blood- borne viruses in prison settings

European Centre for Disease Prevention and Control; European Monitoring Centre for Drugs and Drug Addiction (2018) C2

Guidance Brief Selected findings from ECDC and EMCDDA scientific guidance, 2018

Download (613)

View PDF (716)

Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD) Profile: Sierra Leone

Institute for Health Metrics and Evaluation (2010) C1

Download (210)

View PDF (313)

Good Practices in Mental Health and Well-being

European Union EU (2016) CC

Download (167)

View PDF (199)

Advancing women's leadership and Advocacy for AIDS action

T. Leonhardt; K. Mangino; S. Richiedei; et al. cedpa (The Centre for Development and Population Activities); ICRW ( International Center for Research on Women); ICW Global (The International Community of Women Living with HIVAIDS); et al. (2010) C2

Training Manual

Download (148)

View PDF (156)

Social Protection and Disability in Kenya. Working paper

Kabare K. Development Pathways (2018) C1

Download (688)

View PDF (808)

DISABILITY AND HIV & AIDS IN LESOTHO

Lesotho National Federation of Organisations of the Disabled (LNFOD) (2008) C2

Download (451)

View PDF (429)

Extensive review of tuberculosis prevention, control and care in Armenia 17–25 July 2014

World Health Organization Europe (2015) C_WHO

Download (82)

View PDF (98)

Asthma in South African adolescents: a time trend and risk factor analysis over two decades

Baard, C.B.; Franckling-Smith, Z.; Munro, J. et al. ERJ Open Research (2021) CC

The article "Asthma in South African adolescents: a time trend and risk factor analysis over two decades" investigates the prevalence and risk factors for asthma in Cape Town adolescents from 2002 to 2017. The study finds that while the overall prevalence of asthma remained similar, the severity of ... more

Download (248)

View PDF (196)

Prevention and control of noncommunicable diseases in Ethiopia: The case for investment, including considerations on the impact of khat

World Health Organization WHO (2020) C_WHO

In 2016, the risk of premature mortality1 from noncommunicable diseases (NCDs) in Ethiopia was 18.3%. The economic costs of NCDs are significant and are due principally to their impact on the non-health sector (reduced workforce and productivity). In this study, it is estimated that NCDs cost Ethiop... more

Download (203)

View PDF (202)

Promoting Positive Environments for Women and Girls - Guidelines for Women and Girls Friendly Spaces in South Sudan

UNICEF (2015) C_UNICEF

The creaNon of ‘friendly spaces’ for women and girls has been a key strategy in the protecNon and empowerment of women 1 and girls in South Sudan since conflict re-erupted in the country in December 2013. This document provides guidance on the aims of these spaces, and how they can best be e... more

Download (148)

View PDF (178)

Reopening schools in Latin America and the Caribbean: key points, challenges, and dilemmas to plan a safe return to in-person classes

Inter-American Development Bank IDB, UN Educational, Scientific and Cultural Organization UNESCO (2021) C1

The document presents an assessment developed by both institutions as a contribution to the prioritization of education in national response plans to the health emergency and future recovery strategies. "Countries have deployed various response and recovery plans in which education needs to be incor... more

Download (352)

View PDF (410)

Non-communicable diseases in Mozambique: risk factors, burden, response and outcomes to date

Carla Silva-Matos; David Beran (2012) C1

This revision covers the main non-communicable diseases in Mozambique as well as the National Strategic Plan's aim to create a positive environment to minimize or eliminate the exposure to risk factors and guarantee access to care.